Immix Biopharma prices 16.8M share offering at $0.01 per share
Immix Biopharma is conducting an underwritten public offering of approximately 16.8 million shares of common stock at $0.01 per share with Morgan Stanley as lead underwriter. The o…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Immix Biopharma is conducting an underwritten public offering of approximately 16.8 million shares of common stock at $0.01 per share with Morgan Stanley as lead underwriter. The o…
Conduent has agreed to sell its Public Transit business to Modaxo for $164 million, expected to close before end of 2026. The divestiture is part of Conduent's portfolio simplifica…
Talen Energy Supply refinanced its credit facility through Amendment No. 6 with a consortium of major banks as lead arrangers. The amendment modifies existing term loan structures,…
Radian Group Inc. has entered into an employment agreement with Michael Weinbach to serve as Chief Executive Officer, with an initial term through December 31, 2029 and automatic r…
Daktronics extended a consulting agreement with Carla Gatzke through August 28, 2026, reducing the monthly fee to $7,500 for project-specific advisory services. The amendment repre…
Veritone, Inc. entered into a sales agreement with three underwriters to offer shares of common stock on an at-the-market basis. The offering provides the company with flexibility …
Cyngn achieved record expansion with autonomous missions completed surging 127% year-over-year and autonomous driving time up 60% in Q1 2026, driven by deeper enterprise customer a…
Portillo's Hot Dogs has engaged Pamela F. Smith as Interim Chief Financial Officer through a consulting agreement effective May 20, 2026, at $728,000 annually. The interim role wil…
NKGen Biotech and its operating subsidiary amended their secured convertible loan agreement to receive an additional $412,500 in funding from AlpineBrook Capital GP I Limited, with…
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib showing 15.2 months median PFS and 86% CNS ORR in frontline NSCLC patients with EGFR non-classical mu…
SharonAI Holdings Inc. executed an indenture for convertible senior notes with a 6.00% coupon maturing in 2031, with U.S. Bank Trust Company as trustee. The offering provides the c…
GSR V's May 15, 2026 balance sheet reveals substantial doubt about the company's ability to continue as a going concern due to limited cash and significant business combination pur…
Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs, with anticipated IND submissions over the nex…
Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17, 2026, issuing 10.5M Series B Preferred shares to Faeth shareholders and simultaneously raisin…
Relay Therapeutics launched an underwritten public offering of approximately 22.9 million shares of common stock with an option for underwriters to purchase an additional 3.4 milli…
SEACOR Marine Holdings obtained lender consent to release $13.7 million from escrow and cancelled all undrawn Tranche B commitments under its November 2024 credit agreement. The ac…
GCI Liberty submitted an exhibit filing with the Nevada Secretary of State regarding corporate governance documentation. The filing appears to be a routine administrative matter wi…
WhiteFiber secured a five-year, $160 million AI infrastructure agreement with an investment-grade customer in Paris, deploying NVIDIA GPU systems starting July 2026. The deal demon…
Zelenectide pevedotin combined with pembrolizumab demonstrated response rates comparable to standard of care in metastatic urothelial cancer with approximately four-fold lower skin…
Olema Pharmaceuticals announced encouraging initial clinical data from Phase 1 testing of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in two-…